Abstract:
OBJECTIVE To establish the drug use evaluation(DUE) standard of ticagrelor, and to provide a reference for the rational clinical application of ticagrelor.
METHODS Based on the ticagrelor drug label, related guidelines and literature, combined with clinical expert consultation results, DUE standard from three levels (indications, medications and medication results) was established. A retrospective survey was conducted to evaluate the inpatients using ticagrelor from January 2021 to December 2021 in the Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine.
RESULTS The DUE of ticagrelor was divided into three levels, including 3 first-level indexes, 14 second-level indexes and 60 third-level indexes. A total of 263 cases of using ticagrelor were included, of which the irrational rate was 72.62%. The irrational cases were mainly off-label use (60.08%), inappropriate drug conversion(14.83%) and unreasonable usage and dosage(5.70%), etc.
CONCLUSION The established DUE standard of ticagrelor is scientific, practical and feasible, which can provide reference for clinical rational drug use and prescription evaluation.